Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,916,523
  • Shares Outstanding, K 58,753
  • Annual Sales, $ 94,390 K
  • Annual Income, $ -346,030 K
  • 60-Month Beta 2.31
  • Price/Sales 19.80
  • Price/Cash Flow N/A
  • Price/Book 3.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.85
  • Number of Estimates 5
  • High Estimate -1.71
  • Low Estimate -1.95
  • Prior Year -1.63
  • Growth Rate Est. (year over year) -13.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.02 +5.16%
on 10/10/19
38.90 -16.14%
on 09/12/19
-5.28 (-13.93%)
since 09/11/19
3-Month
31.02 +5.16%
on 10/10/19
49.46 -34.05%
on 07/18/19
-13.04 (-28.56%)
since 07/11/19
52-Week
31.02 +5.16%
on 10/10/19
74.25 -56.07%
on 11/08/18
-30.74 (-48.52%)
since 10/11/18

Most Recent Stories

More News
Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the single agent dose-escalation portion of...

AGIO : 32.62 (+2.55%)
Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma.

AZN : 43.98 (+0.92%)
LLY : 108.36 (+1.35%)
AGIO : 32.62 (+2.55%)
CELG : 100.57 (+0.76%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (AGIO , SRPT , SGEN , ACAD , EXEL )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AGIO : 32.62 (+2.55%)
SRPT : 83.99 (+0.61%)
SGEN : 81.71 (-1.08%)
Shares of AGIO Down 28.5% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Agios Pharmaceut (NASDAQ:AGIO) on July 3rd, 2019 at $46.69. In approximately 3 months, Agios Pharmaceut has returned 28.46% as of today's recent price of $33.40.

AGIO : 32.62 (+2.55%)
Watch for Agios Pharmaceut to Potentially Rebound After Falling 6.44% Yesterday

Agios Pharmaceut (NASDAQ:AGIO) traded in a range yesterday that spanned from a low of $32.05 to a high of $34.59. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of...

AGIO : 32.62 (+2.55%)
Data from Agios' Phase 3 ClarIDHy Trial of TIBSOVO(R) Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

- TIBSOVO Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p

AGIO : 32.62 (+2.55%)
Agios Pharmaceut Set to Possibly Pullback After Yesterday's Rally of 2.18%

Agios Pharmaceut (NASDAQ:AGIO) traded in a range yesterday that spanned from a low of $36.03 to a high of $37.75. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high...

AGIO : 32.62 (+2.55%)
Agios Pharmaceut Shares Down 22.8% Since SmarTrend's Sell Call (AGIO)

SmarTrend identified a Downtrend for Agios Pharmaceut (NASDAQ:AGIO) on July 3rd, 2019 at $46.69. In approximately 3 months, Agios Pharmaceut has returned 22.81% as of today's recent price of $36.04.

AGIO : 32.62 (+2.55%)
Downtrend Call Working As Agios Pharmaceut Stock Falls 19.1% (AGIO)

SmarTrend identified a Downtrend for Agios Pharmaceut (NASDAQ:AGIO) on July 3rd, 2019 at $46.69. In approximately 2 months, Agios Pharmaceut has returned 19.06% as of today's recent price of $37.79.

AGIO : 32.62 (+2.55%)
Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO(R) in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the Phase 3 ClarIDHy study of TIBSOVO in previously...

AGIO : 32.62 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AGIO with:

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 33.51
1st Resistance Point 33.07
Last Price 32.62
1st Support Level 32.07
2nd Support Level 31.51

See More

52-Week High 74.25
Fibonacci 61.8% 57.74
Fibonacci 50% 52.64
Fibonacci 38.2% 47.53
Last Price 32.62
52-Week Low 31.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar